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Urokinase and macrophages in tumour angiogenesis
R Hildenbrand, I Dilger, A Horlin and HJ Stutte
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Summary Recent studies have shown that elevated levels of urokinase plasminogen activator (uPA) and
plasminogen activator inhibitor 1 (PAI-1) in breast cancer correlate with an increased risk of a reduced
relapse-free survival time and shortened overall survival times. Urokinase PA and PAI-I are independent
prognostic indicators for breast cancer. The fact that plasminogen activators are indispensable for tube
formation of microvascular cells and that they may induce angiogenesis in vitro strongly suggests a role for
uPA and PAI-I in tumour neovascularisation. Because macrophages and tumour cells produce uPA, we
postulate a close collaboration between tumour cells and tumour-associated macrophages in angiogenesis. To
investigate how uPA levels and macrophage counts in tumour tissue correlate with angiogenesis, we counted
microvessels and determined uPA levels and macrophage content in 42 primary invasive breast carcinomas.
Using light microscopy, we highlighted the vessels by staining their endothelium cells immunocytochemically
for CD31 and factor VIII and the macrophages for CD68. After obtaining tumour tissue extracts, we
determined the uPA and PAI-I levels by ELISA. A positive correlation between microvessel density, vascular
invasion, uPA level, macrophage content and proliferation rate was found.
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Neoplastic tissues synthesise and secrete proteases which can
degrade extracellular matrix (ECM) constituents, and thereby
facilitate the migration ofmalignant cells through anatomical
barriers (Goldfarb and Liotta, 1986). Among the diverse
extracellular proteolytic enzymes produced by tumours,
urokinase plasminogen activator (uPA) is considered to play
a pivotal role in tissue invasion, vascular invasion and forma-
tion of metastases (Dano et al., 1985).
Tumour cells synthesise and secrete uPA as an inactive
proenzyme (pro-uPA) (Stump, 1986), which binds to specific
receptors on the cell surface (Vasalli et al., 1985). After
binding, pro-uPA is activated by cathepsin B or plasmin
(Kobayashi et al., 1990). Receptor-bound active uPA con-
verts plasminogen to plasmin. Subsequently, plasmin is also
bound to a different receptor on the tumour cell surface
(Miles and Plow, 1988). Plasmin then degrades components
of the stroma (e.g. fibrin, fibronectin, proteoglycans,
laminin), and may activate procollagenase type IV, which
then degrades collagen type IV, a major part of the basement
membrane (Dvorak, 1986). Thus uPA promotes the dissol-
ution of the tumour matrix and the basement membrane,
which is a prerequisite for invasion and metastases. This
implies that the proteolytic activity of uPA also causes a
degradation of vessel walls. Vessel wall dissolution is one of
the first steps in neovascularisation (Mahadevan and Hart,
1990). Furthermore, some ECM molecules become angio-
genic after hydrolytic degradation (West et al., 1985 and
West and Kumar 1989).
Neovascularisation can also be a consequence of fibrin
deposition (Liu et al., 1990) because it serves as a migratory
matrix for endothelial cells and leucocytes (Brown et al.,
1989), and because its plasmin-cleaved fragments such as
fragment E (Thompson et al., 1992) have a strong angiogenic
potential. Fibrin deposition results from extravasation and
subsequent coagulation of plasma fibrinogen. For extravasa-
tion of the large fibrinogen molecule the permeability of the
vasculature must be markedly increased (Brown et al., 1989).
Macrophages can increase vascular permeability by releasing
vasoactive substances (Berse et al., 1992).
Furthermore, it has recently been demonstrated that exp-
ression of uPA by macrophages leads to the plasmin-
dependent release of matrix-bound heparan sulphate proteo-
glycan, basic fibroblast growth factor, and transforming
growth factor beta (Falcone et al., 1993 a,b). Both substances
are known to be strong angiogenic factors.
The fact that breast cancer tissues as well as other malig-
nant tumours often contain large numbers of macrophages
(Van Netten et al., 1993) together with the above-mentioned
aspects, strongly suggests the hypothesis that tumour cells
and tumour-associated macrophages, both releasing uPA,
have a close co-operation in inducing angiogenesis and in
promoting tumour progression and metastases.
Patients and methods
Patients
In a prospective study we examined tumour specimens from
42 patients with primary breast carcinoma. The patients were
randomised, and specimens selected from approximately
equal numbers of patients with positive nodes and patients
with negative nodes. Twenty-two patients were considered to
have positive and 20 to have negative nodal status. One
patient with negative nodes was shown to be positive for
distant metastases. The patients with distant or lymph node
metastases (n = 23), and the patients without metastases
(n = 19) did not differ significantly in tumour grade, tumour
size, number of lymph nodes examined, or age (see statistical
analysis below). Thirty-four carcinomas were of an infiltr-
ating ductal type, seven were of an infiltrating lobular type
and one was of an invasive tubular type. Fourteen tumours
were more than 1.0 cm but not more than 2.0 cm in size.
Twenty-five tumours were more than 2.0 cm, but not more
than 5.0cm and three tumours were more than 5.0cm.
Tumour sections were stained with haematoxylin and
eosin, and graded according to the Scarff-Bloom Richardson
criteria (Le Doussal et al., 1989). Five tumours were grade I,
32 grade II, five were grade III. Immunohistochemical reac-
tions were performed using antibodies against oestrogen
receptors, progesterone receptors, uPA antigen, CD31, factor
VIII, CD68 and Ki-67 by modified alkaline phosphatase/
anti-alkaline phosphatase method (APAAP) (Cordel et al.,
1984).
After immunohistochemical stainings for CD68, we graded
the macrophage fraction on a scale of 1 + to 4 +. The Ki-67
growth fraction reflects the percentage of positively stained
cells in the tumours.
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Tissue extraction
Breast cancer tissue specimens were obtained at surgery and
stored at - 80'C until extraction. In every case we produced
two tissue extracts, one sample was gained from the tumour
margin and another one from central portions of the tumour.
Deep-frozen specimens of 300-400 mg wet weight were
pulverised by conventional mesh graters. The resulting
powder was suspended in 1.8 ml ofTris-buffered saline (TBS;
0.002 M Tris-HCl, 0.125 M sodium chloride, pH 8.5) and
0.2 ml of the non-ionic detergent Triton X-100 10% (Sigma,
Munich, Germany), yieldihg a 1% Triton X-100 final
preparation.
After gentle stirring for 12 h at 4'C, the suspension was
subjected to ultra-centrifugation (100 000 g for 60min, 4°C)
in order to separate cell debris, nuclei and all cell memb-
ranes. The total protein content of the extract was measured
by using a conventional biuret-protein reaction assay. The
detergent Triton X-100 present in the tissue extracts does not
interfere with the protein determination assay. Urokinase PA
and PAI-I were determined in the Triton X 100 extract and
calculated per mg of tissue protein.
Laboratory assay
We performed a uPA and a PAI-I ELISA using a commer-
cially available ELISA kit (American Diagnostica, Greenwich
CT, USA). Microtitre plates (96 wells) were precoated with
monoclonal antibody to human uPA (no. 394; American
Diagnostica). An aliquot of 100 ,ul of 1:20 diluted tissue
extracts (1% bovine serum albumin; BSA-TBS) and uPA
standard were added to microtest wells, and incubated over-
night at 4'C in a humid chamber. Measurements were per-
formed in duplicates. The uPA was detected by biotinylated
monoclonal antibody to human urokinase followed by the
addition of peroxidase-conjugated avidin and 3, 3', 5, 5'
-tetramethylbenzidine as substrate. Absorbance was mea-
sured at 450 nm by an automated microtitre plate reader
(Behring ELISA Processor II, Germany). Recombinant sc-
uPA served as the standard in the uPA ELISA, whose lower
limit of detection is 10 pg ml-'. Different forms of uPA such
as pro-uPA, HMW-uPA and LMW-uPA were recognised. In
addition, uPA complexes with PAI-I or -2, or complexes
with the uPA-receptor were detected. Exposure of uPA to
various proteases did not affect the determination (Schmitt et
al., 1989).
PAI-I was determined using a commercially available
ELISA kit (American Diagnostica type Immubind no. 821).
Recombinant PAI-I was used as the standard in the PAI-i
ELISA. The lower detection limit ofPAI-I ELISA was 50 pg
PAI-I ml-'. The assay detected latent (inactive) and active
forms of PAI-i and PAI-I complexes. This assay was insens-
itive to PAI-2.
Vessel staining, grading and counting
All vessels were highlighted by staining endothelium cells for
CD31 and factor VIII (Dako Diagnostica, Hamburg, Ger-
many) by the use of the APAAP method. Representative
areas of the invasive component of the cancer were selected
from sections stained with haematoxylin and eosin. Often,
these areas contained some in situ carcinoma. Areas of
invasive tumour containing the most capillaries and small
venules (areas of most intense neovascularisation) were
examined by light microscopy. Tumours were frequently
heterogeneous in their microvessel density, but the areas of
highest neovascularisation were found by scanning the
tumour sections at lower power (40 x and 100 x ) and iden-
tifying the areas of invasive carcinoma with the highest
number of discrete microvessel stainings.
There was no significant difference in vessel density
between CD31 and factor VIII staining. The areas of high
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neovascularisation could occur anywhere in the invasive
tumour, but were most frequent at the margins of the car-
cinoma.
After the area of highest neovascularisation was identified
and graded on a scale of 1 + to 4 +, single microvessels were
counted on a 200 x field (20 x objective lens and 10 x
ocular lens; 0.7 mm2 per field) and 400 x field (40 x objec-
tive lens and 10x ocular lens; 0.18mm2 per field). Any
red-staining endothelial cell or endothelial cell cluster that
was clearly separate from adjacent microvessels or tumour
cells was considered as a single, countable microvessel. Each
count was expressed as the highest number of microvessels
identified within any 200 x and 400 x field. Tumour vas-
cular invasions (angioinvasions) were counted on the 400 x
a
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Figure 1 (a) Tumour cells are just breaking through the vessel
wall (arrow). APAAP stain for CD31 (400 x) (b). Vascular
invasion. APAAP stain for CD31 (400 x).
9
Figure 2 High-grade intraductal carcinoma in the vicinity of an
infiltrating peripheral tumour area. APAAP stain for uPA
antigen (400 x).
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field, which were also used for determination of the vessel
density. The criteria for identification of intravascular
tumour were: (1) that tumour cells be clearly seen either
within vessels (Figure lb), or breaking through vessel walls
(Figure la) which were well stained for CD31 or factor VIII.
(2) that the cytological features of intravascular tumour cells
resemble those of adjacent infiltrating tumour cells.
To improve the accuracy of microvessel counts determined
with the technique used in this study, a second investigator
repeated the vessel counts (at 200 x and 400 x ) and grading
of the same tumours. He had no previous knowledge of the
counts and grades obtained by the first investigator.
Although the agreement was not 100% in every case, linear
regression showed that the second investigator's counts corr-
elated highly with those of the first one (density-grading
correlation coefficient r = 0.87, P<0.01; counts at 200 x
r = 0.91, P<0.01, counts at 400 x r = 0.93; angioinvasion
counts, r = 0.78, P<0.01) Microvessel counts and density
grades were determined without knowledge of the patients'
outcome, the presence or absence of metastases or any other
pertinent variables.
Statistical analysis
The Wilcoxon-Mann-Whitney U-test (rank-sum test) was
used for all statistical analyses. For evaluation of differences
in uPA levels ofcentral and peripheral portions ofcarcinoma
we used Wilcoxon's matched pairs signed rank test. Results
are expressed as the mean ± standard error of the mean
(s.e.m.) and are considered significant at the P<0.05 level
(two-tailed). Correlations between uPA, PAI-1, vessel density
and vascular invasion counts were calculated by the method
of Pearson and Spearman.
Results
The main results are listed in Table I. For the antigens uPA
and PAI-I the difference between node-negative and node-
positive patients was statistically significant, although a con-
siderable variation ofuPA and PAI-I content was noted. The
uPA levels of peripheral tumour areas were significantly
Table 1 Histological and clinical characteristics of 42 patients with
breast cancer according to the presence or absence of metastatic
disease
Metastases Metastases
present absent
Characteristic (n = 23) (n = 19) P-value
uPA (peripheral) 5.3 ± 0.76 3.29 ± 0.67 <0.01
(ng mg ')
uPA (central) 2.14 + 0.27 1.99 ± 0.25 NS
(ng mg ')
PAI-I (ngmg') 3.88 ± 0.74 2.23 ± 0.53 <0.05
Vessel density 92.9 10.5 45.3 ± 4.82 <0.01
(per 200 x field)
Vessel density 37.9 ± 3.69 25.3 ± 2.13 <0.05
(per 400 x field)
Vessel densitya 2.65 _ 0.23 1.79 ± 0.15 <0.05
(grading)
Angioinvasion 4.43 ± 0.75 1.95 ± 0.35 <0.05
(per 400 x field)
Tumor grade' 2.39 ± 0.1 2.0 ± 0.13 NS
Tumor size 3.32 ± 0.44 2.35 + 0.22 NS
No. oflymph 12.8 1.53 14.4± 1.1 NS
nodes examined
Age (years) 58.0 2.65 52.9 ± 2.8 NS
ER (fmol mg ') 75.0 ± 18.4 134.2 ± 42.1 NS
PR (fmol mg') 192.2 ± 43.5 256.7 ± 54.2 NS
Ki-67 (%) 28 ± 3 19 ± 1.9 <0.05
Macrophage grade 2.56 ± 0.21 2.05 ± 0.2 NS
(*)
aOn a scale of I to 4 +; see Patients and methods. 'According to the
Scarff-Bloom Richardson classification. NS, not significant; ER,
oestrogen receptor; PR, progesterone receptor.
higher (4.39 ± 0.53 ngmg-'; P<0.05) than in central breast
cancer portions (2.07 ± 0.18). In the case of carcinomas
smaller than 1.5 cm (n = 9), the uPA content was 1.93
± 0.46 ngmg-' in peripheral and 1.90 ± 0.46 ngmg-' in cen-
tral tumour areas. We found virtually no differences in uPA
levels of central tumour areas in patients with and without
metastases, but there was a large and statistically significant
difference in peripheral tumour parts of the same groups.
This result could be confirmed and verified in corresponding
histological sections stained for uPA antigen. Another obser-
vation in these stainings deserves special emphasis. Tumour
cells in high-grade duct carcinoma in situ have a stronger
staining for uPA than invasive tumour cells in their vicinity
(Figure 2). We interpreted this powerful staining as a sign of
activation of these potentially invasive tumour cells for deg-
rading the basement membrane and becoming invasive.
A moderate correlation between uPA and PAI-I levels
exists (r = 0.79); PAI-i is inversely related to steroid hor-
mone receptors (Figure 3). PAI-1 may be subject to hormone
regulation. This is particularly well established in the case of
the inhibitor in the rat hepatoma cell line HCT (Gelehrter et
al., 1983).
The mean microvessel counts in node-positive patients in
areas of highest neovascularisation were 92.9 ± 10.5 per
200 x field and 37.9 ± 3.7 per 400 x field. In the tumours of
the patients without metastases, the corresponding values
were 45.3 ± 4.8 per 200 x field and 25.3 ± 2.1 per 400 x
field. The carcinomas of patients with metastases had a mean
microvessel density grade of 2.65; the carcinomas of the
patients without metastases had a grade of 1.79 (P<0.05).
The average vessel counts were a little higher with CD31
staining than with factor VIII staining. There was a close
correlation between CD31 and factor VIII staining, sugges-
ting that both stainings are reliable methods of quantifying
angiogenesis in tumour tissues.
The mean ofangioinvasion was 3.31 ± 0.48 per 400 x field,
which means that 10.2 ± 1.5% of all endothelium cell-lined
channels had tumour vessel invasions. The difference between
node-negative (7.7 ± 1.4%) and node-positive (11.7 ± 1.9%)
patients was significant at the P<0.05 level.
There was a close correlation between vessel density
(200 x field) and peripheral uPA level (r = 0.85; P<0.01;
95% confidence interval 0.74-0.91). The correlation was still
significant when the patients were separated into node-
negative and node-positive groups (Table II).
The Ki-67 proliferation rates (23.9 ± 2.7%, n = 42) differ
significantly in node-positive (28 ± 3%) and node-negative
(19 ± 1.9%) patients (P<0.05). We have found a high corr-
elation between the Ki-67 growth fraction and the uPA levels
(r=0.91, P<0.001) (Figure 4).
The macrophage grading did not differ significantly in
node-positive (2.56 ± 0.21) and node-negative (2.05 ± 0.2)
patients. In agreement with Muller et al. (1992), we found a
ubiquitous distribution of macrophages and a preponderant
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Figure 3 PAI-1 is inversely related to steroid hormone receptors.
PR, progesterone receptor.localisation within the tumour stroma, but virtually no
accumulation around hot spots of vascular proliferation. The
macrophages were most frequent and in a high density at the
margins of tumour cell islands. Sometimes they were
localised within tumour islands (Muller et al., 1992).
Discussion
This study shows a significant correlation between the uPA
and PAI-1 levels of breast cancer tissue extracts and the
r=0.91 P<0.001 n=42
95% Cl: 0.84 < r< 0.95 0,9
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Figure 4 A high correlation between the Ki-67 growth fraction
and the uPA levels exists.
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Figure 5 Correlation of uPA level and vessel count per 200 x
field (vessel density); n = 42, r = 0.85, P<0.05.
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density of microvessels and vascular invasion in histological
sections (Figure 5). It is known that the first step in
angiogenesis is a proteolytic degradation of vessel walls, and
it is thought that this initiation of neovascularisation is trigg-
ered by collagenases, including type IV, and plasminogen
activators released by endothelium cells (Mahadevan et al.,
1990).
Our results support the hypothesis that uPA and enzymes
which disrupt vessel walls start their degradation, and thus
neovascularisation, at the exterior vessel side after being
released by tumour cells. The enzyme-caused vessel wall diss-
olution is a known stimulus which leads to a proliferation of
endothelium cells, supported by various angiogenic factors,
and subsequently to the formation of new blood vessels.
Thus uPA and perhaps other proteolytic enzymes released by
tumour cells may be involved in the initiation of angio-
genesis; uPA may be an indirect angiogenic factor in vivo.
Furthermore, the invasive chemotactic behaviour of endo-
thelial cells at the tips of growing capillaries is facilitated by
plasminogen activators and collagenases released by tumour
cells as well as endothelium cells (Moscatelli et al., 1981).
On the other hand, proliferating capillaries have frag-
mented basement membranes and are leaky, making them
more penetrable by tumour cells than mature vessels (Nagy
et al., 1989). This may be an important factor which explains
our result concerning the tumour vessel invasion. Tumours
possessing high levels of uPA have 9% more vascular
invasions than carcinomas with an uPA level lower than
3 ng mg-'. This entry of tumour cells into circulation is the
beginning of metastatic processes and may explain clinical
investigations concerning uPA and breast cancer.
The fact that plasminogen activators are indispensable for
tube formation of microvascular cells, and that they may
induce angiogenesis in vitro (Yasunaga et al., 1989; Sato et
al., 1993), strongly suggests a role for uPA in tumour neovas-
Table III Vessel density grade and macrophage grade
Grade 1 2 3 4
Vessel density grade (n) 10 17 9 6
Percentage 23.8 40.5 21.4 14.3
Ki-67 (%) mean 11.1 21.3 28 46.7
uPA (ngmg-') mean 1.1 3.5 5.4 9.9
Macrophage grade (n) 8 18 10 6
Percentage 19 42.8 23.8 14.3
Ki-67 (%) mean 11.5 19 30.2 44.8
uPA (ngmg-') mean 1.2 2.96 5.98 10.3
Table II Interesting correlations
Correlation r r(s) 95% CI P-value
uPA(p) vs vessel 0.85 0.92 0.74-0.91 <0.01
density (n = 42)
uPA vs vessel density 0.91 0.93 0.79-0.96 <0.001
(node positive)
(n = 23)
uPA vs vessel density 0.84 0.97 0.62-0.94 <0.001
(node negative)
(n= 19)
uPA (p) vs angio- 0.79 0.88 0.64-0.88 <0.001
invasion (n = 42)
PAI-i vs uPA 0.79 0.90 0.64-0.88 <0.01
(n = 42)
PAI-I vs vessel 0.74 0.86 0.56-0.85 <0.01
density
Vessel count 0.87 0.90 0.69-0.91 <0.01
(F VIII vs CD31)
(n = 42)
Ki-67 vs uPA 0.91 0.95 0.84-0.95 <0.001
(n = 42)
ER vs PAI-i -0.42 -0.85 -0.69 to -0.12 <0.05
PR vs PAI-I -0.59 -0.89 -0.85 to -0.56 <0.01
r, Pearson's correlation coefficient; r(s), Spearman's correlation coefficient;
95% CI, 95% confidence interval; ER, oestrogen receptor; PR, progesterone
receptor.
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cularisation. We postulate a close collaboration between
tumour cells and tumour-associated macrophages in angio-
genesis. The importance of macrophages in angiogenesis
results from three qualities:
(1) Macrophages are resident in all breast carcinomas in
larger numbers than other blood-borne cells, and distinct
subtypes of macrophages can always be recruited from
the bloodstream (Muller et al., 1992).
(2) They are functionally heterogeneous and can be activated
from a quiescent non-angiogenic stage to an angiogenic
stage (Assoian et al., 1987).
(3) Angiogenesis is a multistep process for which changes in
the ECM have to be combined with the coordinated
supply of appropriate angiogenic factors. Macrophages,
0
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Figure 6 High uPA levels cause an increase in the percentage of
vascular invasions. s.e.m. = standard error of the mean.
Figure 7 Peripheral tumour area. Strong uPA reaction in close
vicinity of a vessel. APAAP stain for uPA antigen (200 x).
and especially distinct subtypes of macrophages, are
capable of providing several cytokines for the initiation,
the maintenance and the termination of the angiogenic
process.
The connection between vessel density grade, macrophage
grade, Ki-67 growth fraction and uPA level is represented in
Table II1. These results indirectly suggest a collaboration
between macrophages and tumour cells in angiogenesis.
Recent studies have shown that elevated uPA and PAI
levels in breast cancer tumour tissue correlate significantly
with a shortened time until first recurrence and a shortened
overall survival time in breast cancer patients, and that both
enzymes are independent prognostic factors in node-negative
breast cancer patients (Janicke et al., 1990, 1993; Foekens et
al., 1992). The essential findings in these studies were that
breast cancer patients with either high uPA or high content
of uPA inhibitor PAI-I in their primary tumours have an
increased risk of relapse and death. Our results partly
confirm and explain these clinical investigations; high uPA
levels are correlated with high vessel densities. This means
that patients with high uPA levels have a greater vessel
density and higher percentage of vascular invasions com-
pared with patients who exhibit low uPA levels (Figure 6).
Thus the tumour cell entry into circulation may happen more
frequently at an early time, and it is this early tumour
dissemination which leads to a shortened overall survival
time.
An important result of this study is that central portions of
breast carcinoma contain less uPA antigen than peripheral
tumour parts. This was confirmed by the evaluation of histo-
logical sections stained for uPA antigen (Figures 7 and 8).
This agrees with other authors who have found that in Lewis
lung carcinoma uPA was located in the invading parts of the
tumour, often in areas in which active infiltration and tissue
destruction was taking place (Skriver et al., 1984).
This is in agreement with the fact that the areas of high
neovascularisation were most frequent at the margins of the
carcinoma. This heterogeneous distribution of uPA in breast
cancer suggests that the tissue used for extraction should be
taken at the tumour margins.
On the other hand, we did not find significant differences
in uPA levels in central compared with peripheral tumour
portions in carcinomas smaller than 1.5 cm. This may be
explained by the difficulty in distinguishing between central
and peripheral areas during tissue extraction and more likely
the entire tumour tissue is the area of active infiltration and
tissue destruction, so that in this confined group of small
tumours the uPA content seems to be homogeneously dist-
ributed.
PAI-I correlates weakly with uPA and with vessel density.
It seems somewhat contradictory that the uPA inhibitor PAI-1
is also important for poor prognosis and that its ranking in
multivariate analysis is close in order to that of uPA (Jinicke
et al., 1991), since one would expect PAI-I to act protectively
by blocking the enzymatic activity of free and receptor-
bound uPA. Jinicke et al. argued that excess release of PAI-1
might be of importance for reimplantation of circulating
tumour cells, since formation of new stroma at the metastatic
site requires the blockade of uPA-mediated degradation of
extracellular matrix.
It was hypothesised that PAI-I levels in tumour extracts
may be a biochemical measure of the extent of neovas-
cularisation (Grondahl-Hansen et al., 1993), since PAI-l may
play a role in angiogenesis (Montesano et al., 1990).
Figure 8 Weak uPA reaction in a central tumour area. APAAP
stain for uPA antigen (400 x).
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